# TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment

Study · id `cardio:ct-nct04951050` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04951050](<https://clinicaltrials.gov/study/NCT04951050>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04951050

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04951050. Allocation not applicable; no masking; primary purpose treatment. Start 2022-02-28 (actual); primary completion 2023-08-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04951050, source copy `cardio:ctgov-nct04951050-2023-11-09`, retrieved 2026-10-26)
- Started: 2022-02-28 (actual) (ClinicalTrials.gov record NCT04951050, source copy `cardio:ctgov-nct04951050-2023-11-09`, retrieved 2026-10-26)
- Primary completion: 2023-08-26 (actual) (ClinicalTrials.gov record NCT04951050, source copy `cardio:ctgov-nct04951050-2023-11-09`, retrieved 2026-10-26)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT04951050, source copy `cardio:ctgov-nct04951050-2023-11-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04951050, source copy `cardio:ctgov-nct04951050-2023-11-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04951050-2023-11-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment
- Acronym: T-P
- Condition: Coronary Artery Disease
- Condition: Coronary Stenosis
- Intervention (Device): Rapamycin target eluting stent
- Lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Shanghai MicroPort Medical (Group) Co., Ltd. (`cardio:org-shanghai-microport-medical-group-co-ltd`)

## Provenance

Content hash: d2d09ce7d555392c9d0d811e6e6cac753f284b5ad7641e27dd6cae2870663aa7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
